DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Lenzilumab
Lenzilumab
Presentation
ヤンセンファ࣮ч株式会社
2017 Immuno-Oncology Medicines in Development
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
Soluble Ligands As Drug Targets
Lenzilumab Efficacy and Safety in Newly
Research Center Spotlight
Stembook 2018.Pdf
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
2018 Medicines in Development for Cancer
Humanigen February 2021 Cautionary Note Regarding Forward-Looking Statements
(INN) for Biological and Biotechnological Substances
Therapeutic Strategies for Targeting IL-1 in Cancer
Immunomodulators Under Evaluation for the Treatment of COVID-19
No Relevant Financial Relationship(S) with Industry: Off-Label Usage
Enduring Materials Application – Medical Grand Rounds #1886
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
Top View
The Society for Immunotherapy of Cancer Perspective on Regulation of Interleukin-6 Signaling in COVID-19- Related Systemic Inflammatory Response
GM-CSF: a Promising Target in Inflammation and Autoimmunity
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Implication of Monoclonal Antibody for Covid-19
Global Spotlight 8.2: Key Additions for the Second Half of August 2021
International Nonproprietary Names for Pharmaceutical Substances (INN)
2020 Medicines in Development ꟷ Cancer
Humanigen May 2021 Cautionary Note Regarding Forward-Looking Statements
Pipeline Report August 2021
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
Horizon Scanning COVID-19 Supplement Status Report, Volume
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
PDF of Antibody News
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Lenzilumab™ Overview Potential in Treating Covid
The Society for Immunotherapy of Cancer Perspective on Regulation of Interleukin-6 Signaling in COVID-19-Related Systemic Inflammatory Response
First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients With
Policy Brief 002 Update 05.2021.Pdf
Novel Biologicals for the Treatment of Allergic Diseases and Asthma
Classification of "Voxtalisib" (Inn List 108) And
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
Medical Product Quality Report
(INN) for Biological and Biotechnological Substances
Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
Antibody-Based Immunotherapeutic Strategies for COVID-19
Immunomodulatory Therapies for SARS-Cov-2 Infection
Antibodies[Version 1; Peer Review: 2 Approved]
Cochrane Library
JHMI Clinical Recommendations For
Cytokine Targeting in Rheumatoid Arthritis T ⁎ Viet L
Spotlight on Mavrilimumab for the Treatment of Rheumatoid Arthritis: Evidence to Date
Ra Capital's Covid-19 Map
Comparing Biologicals and Small Molecule Drug Therapies for Chronic Respiratory Diseases
Humanigen March 2021 Cautionary Note Regarding Forward-Looking Statements
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Therapeutic Antibodies for the Treatment of Respiratory Tract Infections—Current Overview and Perspectives